Sign in now to see personalised content appear here.
You can also see your reading history and subscription details on your subscriber page.
If draft legislation goes ahead, pharmaceutical companies will need to tread carefully, says IP law firm Withers & Rogers
Award will support development of new therapies to target prostate cancer
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Will use Rani's proprietary oral biotherapeutics drug delivery platform to formulate and test selected biologics
Part of aim to focus on areas where most value can be added, says Strides
Huge quantities of aggregated research and real-patient information may hold important keys for future drug discovery. Jaqui Hodgkinson, Elsevier R&D Solutions, looks at the benefits and challenges of harnessing meaningful information quickly and cost-effectively from big data
Partnership has a strong portfolio of generic insulin analogues and biosimilars including monoclonal antibodies (MAbs) and recombinant proteins at various stages of development
Next-Generation Sequencing is revolutionising the study of genomics and molecular biology. Thermo Fisher Scientific explains how it can be used in the design of therapeutic products with a future goal of enabling precision oncology
Group comprises Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech
In addition to proof of drug effectiveness, pharmacovigilance has become an important safety requirement laid down by the regulators. Dr Chitra Lele, CSO, Sciformix Corporation, discusses the importance of establishing an effective global safety framework to meet today’s needs
For increased capacity, recovery and concentration
With R&D and production costs spiralling and the growing regulatory requirements biting into the profit margins of drug sales, the industry needs radical change to manufacturing models, argues Ed Price, President, PCI Synthesis